Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMORY study of mepolizumab on airway physiology in eosinophilic asthma
2015-001868-19Phase 3Terminated
- Sponsor
- University Medical Center Mainz
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Mean change from baseline in airway physiology and lung function at week 24 and at time of response. Started Jul 2015; status: terminated.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2015-001868-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001868-19.